Condition
Anaplastic Thyroid Cancer clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Anaplastic Thyroid Cancer clinical trials that are recruiting, at sites in 4 countries (most in Netherlands (2), Spain (1), United States (1)). By phase: Phase 2 (3), Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 4Countries
Newest Anaplastic Thyroid Cancer clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Personalized drug combos for advanced thyroid cancer | Phase 1 | Nijmegen | Recruiting | Mar 20, 2026 |
| Combining XL092 and cemiplimab for BRAF V600E–wildtype anaplastic thyroid cancer | Phase 1 | Boston, Massachusetts and 1 other locations | Recruiting | Mar 30, 2025 |
| Combining Pembrolizumab and Lenvatinib for Anaplastic Thyroid Cancer | Phase 2 | Saint Petersburg | Recruiting | Apr 18, 2024 |
| Treatment for advanced thyroid cancers using sacituzumab govitEcan | Phase 2 | Barcelona and 10 other locations | Recruiting | Jan 31, 2024 |
| Targeted therapy for BRAF-mutated anaplastic thyroid cancer | Phase 2 | Leiden, South Holland | Recruiting | Oct 12, 2023 |
All recruiting trials (5)
-
Personalized drug combos for advanced thyroid cancer
This phase Ib study tests whether customized drug combinations, chosen from existing approved medicines based on a patient’s tumor genetics, can be safely given to people with advanced thyroid cancer when standard options are limited.
-
Combining XL092 and cemiplimab for BRAF V600E–wildtype anaplastic thyroid cancer
This trial will test whether giving XL092 plus cemiplimab before surgery is safe and doable for adults with BRAF V600E–wildtype anaplastic thyroid cancer.
-
Combining Pembrolizumab and Lenvatinib for Anaplastic Thyroid Cancer
This study is testing if a combination of two drugs, pembrolizumab and lenvatinib, can help people with anaplastic thyroid cancer who haven't been treated before.
-
Treatment for advanced thyroid cancers using sacituzumab govitEcan
This study is testing a new drug called sacituzumab govitEcan to see if it can help people with advanced thyroid cancers that don't respond to traditional treatments.
-
Targeted therapy for BRAF-mutated anaplastic thyroid cancer
This study is testing a new treatment using two targeted drugs to see if it helps patients with a specific type of thyroid cancer have better surgery outcomes.
Related topics
Quick answers
How many Anaplastic Thyroid Cancer clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in Netherlands (2 trials), Spain (1 trial), United States (1 trial), Russia (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.